摘要
目的探究阿帕替尼治疗宫颈癌患者的临床疗效,并分析其对患者血清鳞状细胞癌相关抗原(SCCA)、β2-微球蛋白(β2-MG)、血清神经元特异性烯醇化酶(NSE)表达及预后的影响。方法回顾性分析2016年1-10月华中科技大学医院收治的88例宫颈癌患者为研究对象,按照治疗方式将其分为对照组和观察组,每组各44例。对照组患者给予顺铂注射液治疗,观察组患者给予阿帕替尼治疗,治疗后,比较两组患者临床总有效率、血清SCCA、β2-MG、NSE表达、预后及不良反应发生情况。结果治疗后,观察组患者总有效率(86.36%)显著高于对照组(68.19%),差异有统计学意义(χ^(2)=1.141,P<0.05)。治疗前,两组患者血清SCCA、β2-MG及NSE表达水平[对照组(11.05±1.27)ng/L、(289.47±106.21)ng/ml、(28.45±10.16)pg/ml,观察组(11.01±1.18)ng/L、(288.98±106.14)ng/ml、(28.16±9.79)pg/ml]比较,差异均无统计学意义(t=0.153、0.022及0.136,均P>0.05);治疗后,两组患者血清SCCA、β2-MG及NSE表达水平均显著降低,两组间治疗前后比较,差异均有统计学意义(观察组t=51.587、7.027及10.679,对照组t=44.355、5.670及6.969,均P<0.05),且观察组患者[(1.56±0.29)ng/L、(169.49±38.16)ng/ml、(12.07±2.01)pg/ml]均显著低于对照组[(2.52±0.12)ng/L、(192.26±40.63)ng/ml、(17.56±2.05)pg/ml],差异均有统计学意义(t=20.290、2.710及12.684,均P<0.05)。观察组患者死亡率(2.27%)和不良反应发生率(2.27%)均显著低于对照组(13.64%,15.91%),差异均有统计学意义(χ^(2)=3.880、4.950,均P<0.05)。结论阿帕替尼可有效抑制宫颈癌细胞的增殖和扩散,从而达到有效缓解患者疼痛,改善预后的目的。
Objective To investigate the clinical efficacy of apatinib in the treatment of patients with cervical cancer,and to analyze its influences on serum squamous cell carcinoma antigen(SCCA),β2-microglobulin(β2-MG),serum neuron specific enolase(NSE)expression and prognosis.Methods A retrospective analysis included 88 cervical cancer patients accepted by Huazhong University of Science and Technology Hospital from January to October 2016 as the research objects.According to the treatment methods,they were grouped into a control group and an observation group,with 44 cases per group.The patients in the control group were treated with cisplatin injection,and the patients in the observation group were treated with apatinib.After treatment,the total effective rate,serum SCCA,β2-MG,NSE expression,prognosis and adverse reactions were compared between the two groups.Results After treatment,the total effective rate in the observation group(86.36%)was obviously higher than that in the control group(68.19%),and the difference was statistically significant(χ^(2)=1.141,P<0.05).Before treatment,there was no obvious difference in the expression levels of serum SCCA,β2-MG and NSE[control group(11.05±1.27)ng/L,(289.47±106.21)ng/ml,(28.45±10.16)pg/ml,observation group(11.01±1.18)ng/L,(288.98±106.14)ng/ml,(28.16±9.79)pg/ml]between the two groups(t=0.153,0.022 and 0.136,all P>0.05);after treatment,the expression levels of serum SCCA,β2-MG and NSE in the two groups were greatly decreased,there were statistically significant differences between the two groups before and after treatment(the observation group t=51.587,7.027 and 10.679,the control group t=44.355,5.670 and 6.969,all P<0.05),and the observation group[(1.56±0.29)ng/L,(169.49±38.16)ng/ml,(12.07±2.01)pg/ml]were greatly lower than the control group[(2.52±0.12)ng/L,(192.26±40.63)ng/ml,(17.56±2.05)pg/ml],and the differences were statistically significant(t=20.290,2.710 and 12.684,all P<0.05).The incidence of death(2.27%)and the incidence of adverse reactions(2.27%)in
作者
张继东
胡娟
张世应
孙绪举
ZHANG Ji-Dong;HU Juan;ZHANG Shi-Ying(Department of Pharmacy,Huazhong University of Science and Technology Hospital,Wuhan,Hubei 430074,China)
出处
《中国妇幼保健》
CAS
2022年第7期1181-1184,共4页
Maternal and Child Health Care of China
基金
国家自然科学基金项目(81803018)。
